fbpx Demographic decrease of Stars | Page 422 | Science in the net

Demographic decrease of Stars

Primary tabs

Read time: 2 mins

An international team of astronomers, whilst reconstructing how the pace of the formation of new stars has changed throughout the history of the Universe, discovered that we presently find ourselves faced with a genuine demographic decrease.

Extracting the data gathered using the UKIRT, VLT and Subaru telescopes, David Sobral (Leiden University) and colleagues discovered that half of the stars which are currently present in the Universe, were developed between 9 and 11 billion years ago. Following the birth boom, the demographic growth became increasingly slower: 9 billion years were needed to create the second half of the present stars. According to the researchers, who had access to ten times more data than that available up to the present, with which to conduct the same analysis, the current rate of stellar creation has reduced 30 times when compared to the maximum value.

In addition to the fact that this may concern us directly, the future of the Universe has never looked so gloomy. In the study, which will appear in the next edition of Monthly Notices of the Royal Astronomical Society, it has been suggested that, at this rate, only a further 5% of new stars will be created in the Universe. "We are living in a Universe of old stars - highlights Sobral - and we cannot ignore the fact that our Galaxy is still quite active in terms of stellar creation".

Royal Astronomical Society - Research paper

Autori: 
Sezioni: 
Universe

prossimo articolo

Will anticoagulants be the new blockbuster?

In 2010, the European Medicines Agency (EMA) has approved the lowest number of new drugs in the last decade. This is not surprising, considering that it takes at least 10 years to register a drug, the total cost is about one billion dollars, and that at least 9 out of 10 of those for which clinical development is initiated, fall by the wayside. Some striking example? Rimonabant for obesity and metabolic syndrome, the monoclonal antibody ocrelizumab for rheumatoid arthritis and systemic lupus erythematosus.